Kythera Biopharmaceuticals Inc  

(Public, NASDAQ:KYTH)   Watch this stock  
Find more results for Keith F. Ball
47.63
-1.68 (-3.41%)
May 26 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 47.31 - 49.17
52 week 29.86 - 56.00
Open 49.14
Vol / Avg. 481,128.00/482,188.00
Mkt cap 1.27B
P/E     -
Div/yield     -
EPS -4.16
Shares 25.80M
Beta     -
Inst. own 95%
Aug 5, 2015
Q2 2015 KYTHERA Biopharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 5, 2015
KYTHERA Biopharmaceuticals Inc Annual Shareholders Meeting (Estimated) - 11:00AM EDT - Add to calendar
Jun 2, 2015
KYTHERA Biopharmaceuticals Inc Annual Shareholders Meeting - 11:00AM EDT - Add to calendar
May 14, 2015
KYTHERA Biopharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference
May 7, 2015
Q1 2015 KYTHERA Biopharmaceuticals Inc Earnings Call
May 7, 2015
Q1 2015 KYTHERA Biopharmaceuticals Inc Earnings Release
Apr 29, 2015
KYTHERA Biopharmaceuticals Inc Corporate Call - FDA Approval of KYBELLA(TM) (also known as ATX-101)
Mar 26, 2015
KYTHERA Biopharmaceuticals Inc Corporate Call - Outlook investor - Webcast
Mar 2, 2015
Q4 2014 KYTHERA Biopharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -72.52% -97.98%
Return on average equity -100.44% -129.61%
Employees 106 -
CDP Score - -

Address

27200 Agoura Rd Ste 200
AGOURA HILLS, CA 91301-5127
United States - Map
+1-818-5874500 (Phone)
+1-818-5874591 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

KYTHERA Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of prescription products for the aesthetic medicine market. The Company’s initial focus is on the facial aesthetics market. The Company’s product candidate, ATX-101, is an injectable drug in late-stage clinical development for the reduction of submental fat, which commonly presents as an undesirable double chin. The Company’s ATX-101 treatment contours the area under the chin by destroying fat cells while leaving surrounding tissue largely unaffected. The Company’s Phase II and Phase III studies have demonstrated that ATX-101, when injected subcutaneously into the target fat deposit, reduces the localized fat deposit while leaving the surrounding tissue largely unaffected. It is an attractive non-surgical solution for the reduction of submental fat.

Officers and directors

Keith R. Leonard Jr. President, Chief Executive Officer, Director
Age: 53
Bio & Compensation  - Reuters
John W. Smither Chief Financial Officer
Age: 62
Bio & Compensation  - Reuters
Douglas Rich Vice President - Operations
Age: 46
Bio & Compensation  - Reuters
Keith L. Klein J.D. General Counsel, Secretary
Age: 51
Bio & Compensation  - Reuters
Frederick Beddingfield III, M.D., Ph.D. Chief Medical Officer
Age: 50
Bio & Compensation  - Reuters
Elisabeth A. Sandoval Chief Commercial Officer
Age: 53
Bio & Compensation  - Reuters
F. Michael Ball Independent Director
Age: 59
Bio & Compensation  - Reuters
Nathaniel E. David Ph.D. Independent Director
Age: 47
Bio & Compensation  - Reuters
Dennis M. Fenton Ph.D. Independent Director
Age: 63
Bio & Compensation  - Reuters
Francois Kress Independent Director
Age: 48
Bio & Compensation  - Reuters